PMID- 23521157
OWN - NLM
STAT- MEDLINE
DCOM- 20141216
LR  - 20211203
IS  - 1600-0714 (Electronic)
IS  - 0904-2512 (Linking)
VI  - 42
IP  - 10
DP  - 2013 Nov
TI  - Abundant expression of mTOR kinase in salivary gland tumors - potentials as 
      therapy target?
PG  - 769-73
LID - 10.1111/jop.12064 [doi]
AB  - BACKGROUND: Salivary gland tumors constitute 3-6% of all head and neck neoplasms 
      in adults. Because of limited advances made in the treatment of metastatic 
      disease, the more important is the role of new therapeutic strategies, including 
      molecular therapy. The mammalian target of rapamycin (mTOR) has recently been 
      established as a therapeutic target for several drugs. MATERIAL: Evaluation of 
      phospho-mTOR as a possible therapy target by patients with salivary gland tumors. 
      Immunohistochemical semi-quantitative analyses of the expression of 
      phospho-mTOR(Ser2448) were processed on a tissue microarray containing samples 
      from more than 900 patients. For statistical analysis, contingency table and 
      chi-squared test (likelihood) were used. RESULTS: We observed at least weak 
      phospho-mTOR expression in 25.6-41.2% of all 4 histological adenoma and in 
      36.8-61.6% of all 11 histological carcinoma subtypes analyzed. No association was 
      seen between phospho-mTOR expression and tumor grade in mucoepidermoid 
      carcinomas. CONCLUSION: In conjunction with literature data providing the 
      evidence for a functional role of mTOR in salivary gland tumors, we conclude that 
      treatment with mTOR-antagonists might potentially also be efficient in wide 
      variety of salivary gland carcinomas.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Clauditz, Till Sebastian
AU  - Clauditz TS
AD  - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Gontarewicz, Artur
AU  - Gontarewicz A
FAU - Bokemeyer, Carsten
AU  - Bokemeyer C
FAU - Sauter, Guido
AU  - Sauter G
FAU - Knecht, Rainald
AU  - Knecht R
FAU - Munscher, Adrian
AU  - Munscher A
FAU - Wilczak, Waldemar
AU  - Wilczak W
LA  - eng
PT  - Journal Article
DEP - 20130325
PL  - Denmark
TA  - J Oral Pathol Med
JT  - Journal of oral pathology & medicine : official publication of the International 
      Association of Oral Pathologists and the American Academy of Oral Pathology
JID - 8911934
RN  - 452VLY9402 (Serine)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adenoma/classification/enzymology
MH  - Adult
MH  - Carcinoma/classification/enzymology
MH  - Carcinoma, Mucoepidermoid/enzymology
MH  - Female
MH  - Gene Expression Regulation, Enzymologic
MH  - Humans
MH  - Male
MH  - Molecular Targeted Therapy
MH  - Parotid Neoplasms/enzymology
MH  - Phosphorylation
MH  - Salivary Gland Neoplasms/*enzymology
MH  - Salivary Glands, Minor/enzymology
MH  - Serine
MH  - TOR Serine-Threonine Kinases/*analysis/antagonists & inhibitors
MH  - Tissue Array Analysis
OTO - NOTNLM
OT  - mammalian target of rapamycin
OT  - molecular therapy
OT  - phospho-mTOR
OT  - salivary gland tumors
OT  - target of rapamycin
EDAT- 2013/03/26 06:00
MHDA- 2014/12/17 06:00
CRDT- 2013/03/26 06:00
PHST- 2013/02/28 00:00 [accepted]
PHST- 2013/03/26 06:00 [entrez]
PHST- 2013/03/26 06:00 [pubmed]
PHST- 2014/12/17 06:00 [medline]
AID - 10.1111/jop.12064 [doi]
PST - ppublish
SO  - J Oral Pathol Med. 2013 Nov;42(10):769-73. doi: 10.1111/jop.12064. Epub 2013 Mar 
      25.